BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heresi GA, Dweik RA. Pulmonary hypertension: evaluation and management. Compr Ther 2007;33:150-61. [PMID: 18004030 DOI: 10.1007/s12019-007-0014-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Navaneethan SD, Wehbe E, Heresi GA, Gaur V, Minai OA, Arrigain S, Nally JV Jr, Schold JD, Rahman M, Dweik RA. Presence and outcomes of kidney disease in patients with pulmonary hypertension. Clin J Am Soc Nephrol 2014;9:855-63. [PMID: 24578332 DOI: 10.2215/CJN.10191013] [Cited by in Crossref: 29] [Cited by in F6Publishing: 12] [Article Influence: 3.6] [Reference Citation Analysis]
2 Guazzi M, Myers J, Peberdy MA, Bensimhon D, Chase P, Arena R. Ventilatory efficiency and dyspnea on exertion improvements are related to reduced pulmonary pressure in heart failure patients receiving Sildenafil. International Journal of Cardiology 2010;144:410-2. [DOI: 10.1016/j.ijcard.2009.03.041] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
3 Malerba M, Radaeli A, Olivini A, Damiani G, Ragnoli B, Montuschi P, Ricciardolo FL. Exhaled nitric oxide as a biomarker in COPD and related comorbidities. Biomed Res Int 2014;2014:271918. [PMID: 24719850 DOI: 10.1155/2014/271918] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 6.8] [Reference Citation Analysis]
4 Frampton JE. Ambrisentan. Am J Cardiovasc Drugs 2011;11:215-26. [PMID: 21623643 DOI: 10.2165/11207340-000000000-00000] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
5 Barnes PJ, Dweik RA, Gelb AF, Gibson PG, George SC, Grasemann H, Pavord ID, Ratjen F, Silkoff PE, Taylor DR, Zamel N. Exhaled nitric oxide in pulmonary diseases: a comprehensive review. Chest 2010;138:682-92. [PMID: 20822990 DOI: 10.1378/chest.09-2090] [Cited by in Crossref: 256] [Cited by in F6Publishing: 233] [Article Influence: 21.3] [Reference Citation Analysis]
6 Insel PA, Patel HH. Membrane rafts and caveolae in cardiovascular signaling. Curr Opin Nephrol Hypertens 2009;18:50-6. [PMID: 19077689 DOI: 10.1097/MNH.0b013e3283186f82] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
7 Wang M, Hu Y, Guo B, Tang H. Simulation of Acute Pulmonary Hypertension in Beagle Dogs. Int Heart J 2022;63:612-22. [PMID: 35650161 DOI: 10.1536/ihj.21-676] [Reference Citation Analysis]
8 Giannoni A, Raglianti V, Mirizzi G, Taddei C, Del Franco A, Iudice G, Bramanti F, Aimo A, Pasanisi E, Emdin M, Passino C. Influence of central apneas and chemoreflex activation on pulmonary artery pressure in chronic heart failure. International Journal of Cardiology 2016;202:200-6. [DOI: 10.1016/j.ijcard.2015.09.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
9 Spitale N, Popat N, McIvor A. Update on exhaled nitric oxide in pulmonary disease. Expert Rev Respir Med 2012;6:105-15. [PMID: 22283583 DOI: 10.1586/ers.12.1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
10 Heresi GA, Dweik RA. Sarcoidosis-Associated Pulmonary Hypertension. Chest 2009;135:1410-2. [DOI: 10.1378/chest.08-3040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
11 Guo W, Wang N, Cui Z, Liu W, Guo S, Yang X, Liu Y, Shao L, Wang J, Lin Y. Clinical Value of FeNO for Pulmonary Hypertension Diagnosis in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Emergency Medicine International 2022;2022:1-6. [DOI: 10.1155/2022/9924047] [Reference Citation Analysis]